Untitled design (9).png

Research Involvement

From sponsor-initiated clinical trials to observational cohort studies and investigator-initiated research programs, VIDC makes strides in scientific advancement while providing access to treatment for marginalized and vulnerable populations. 

The overall mission of the VIDC clinical research team is to understand and advance the knowledge of HCV and HIV transmission, infection, prevention and re-infection to recognize how these impact population-level demographics and prevalence. Our research team presents their findings regularly at forums and conferences both nationally and internationally.

The team obtains funding through grants to support community initiatives such as community pop-up clinics, HIV sexual health promotion workshops and weekly patient  support groups. 

Find a list of published papers and conference posters here > 

Copy of Bridging the gap between excelle

Below is a list of observational studies and clinical trials VIDC is currently enrolling in.

If you would like to participate, please reach out to us at info@vidc.ca

Clinical Trials

CAPELLA (GS-US-200-4625)

This study is a randomized, quadruple masked, interventional study. The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR). More information >

DOR/ISL (MK-8591A-019)

This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage of participants receiving DOR/ISL to achieve ≥0.5 log10 decrease in HIV-1 ribonucleic acid (RNA) from study baseline (Day 1) to Day 8 is superior to placebo, each given in combination with failing antiretroviral therapy (ART). More information >


Observational Studies


The purpose of the CANUHC research study is to collect and study information on all types of people living with Hepatitis C, including subjects with cirrhosis (advanced scarring of liver), the elderly, people who inject drugs, among others.


Newer, all-oral, pan-genotypic direct-acting antiviral (DAA) lead to a cure of infection in > 95% of Hepatitis C virus (HCV) cases. Although these well-tolerated, highly effective treatments are widely available to all viremic patients in British Columbia, significant barriers undermine our ability to increase HCV treatment starts, especially in vulnerable inner-city populations. The primary objective is to identify 300 people who use drugs (PWUD) with chronic, viremic HCV infection and engage them in a multidisciplinary, generalizable model of care and initiate HCV treatment. More information >

CoCo (CTN 222)

The Canadian Co-infection Cohort study follows a group of HIV and Hepatitis C (HCV) co-infected patients from 18 centres across Canada. The primary objective of this study is to determine the effect of antiretroviral therapy (ART) on liver disease progression in HIV-HCV co-infection. More information >

Grand Plan

The Grand Plan study is an open label study. The purpose is to determine the effectiveness of providing a multidisciplinary care approach to initiating glecaprevir/Pibrentasvir tablets (G/P) for eight weeks in treating HCV infection.


This is a Phase 2 study to evaluate response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucelos(t)ide analog regimen with or without pegylated interferon alpha-2a in Immune Tolerant patients with Chronic Hepatitis B Infection.